Group 1 - The core viewpoint of the articles highlights the innovative achievements of Jinhe Biological, particularly the acquisition of a patent for a dual-subunit vaccine for cats, which enhances the company's competitive edge in the pet healthcare market [1][2] - The patent allows for a simplified production process that can produce two types of viral subunit vaccines simultaneously, reducing production costs and promoting sustainable innovation within the company [1] - The pet economy in China is experiencing significant growth, with the urban pet consumption scale projected to increase from 170.8 billion yuan in 2018 to 300.2 billion yuan by 2024, reflecting a compound annual growth rate of 9.86% [1] Group 2 - Jinhe Biological has strategically positioned itself in the pet healthcare market by establishing a dedicated pet division in 2019 and a Shanghai branch in 2024, focusing on both imported and domestic brands [2] - The company has developed a diverse product line, including eight natural plant extracts and probiotics, with eleven additional products under application, laying a solid foundation for future market expansion [2] - Jinhe Biological's "Aichongyi" brand received the "2025 Annual Science and Technology Innovation Brand Award," recognizing the company's innovation capabilities and product brand value in the pet medical field [2]